Literature DB >> 8598075

Fibrin-selective thrombolytic therapy for acute myocardial infarction.

D Collen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8598075     DOI： 10.1161/01.cir.93.5.857

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  12 in total

Review 1.  New thrombolytic strategy: bolus administration of tPA and urokinase-fibrinogen conjugate.

Authors:  A V Maksimenko; E G Tischenko
Journal:  J Thromb Thrombolysis       Date:  1999-06       Impact factor: 2.300

Review 2.  Molecular basis of thrombolytic therapy.

Authors:  H R Lijnen; D Collen
Journal:  J Nucl Cardiol       Date:  2000 Jul-Aug       Impact factor: 5.952

3.  The effects of age and gender on the pharmacokinetics and pharmacodynamics in healthy subjects of the plasminogen activator, lanoteplase.

Authors:  Nimish N Vachharajani; Ralph H Raymond; Wen-Chyi Shyu; Bruce C Stouffer; David W Boulton
Journal:  Br J Clin Pharmacol       Date:  2011-11       Impact factor: 4.335

4.  Flow-dependent channel formation in clots by an erythrocyte-bound fibrinolytic agent.

Authors:  Kathryn C Gersh; Sergei Zaitsev; Douglas B Cines; Vladimir Muzykantov; John W Weisel
Journal:  Blood       Date:  2011-03-09       Impact factor: 22.113

5.  Fibrinolytic Enzyme Cotherapy Improves Tumor Perfusion and Therapeutic Efficacy of Anticancer Nanomedicine.

Authors:  Ameya R Kirtane; Tanmoy Sadhukha; Hyunjoon Kim; Vidhi Khanna; Brenda Koniar; Jayanth Panyam
Journal:  Cancer Res       Date:  2017-01-20       Impact factor: 12.701

6.  Management of Acute Ischemic Coronary Syndromes: The Present and Future.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-11       Impact factor: 2.300

7.  NANOMATERIALS FOR PROTEIN MEDIATED THERAPY AND DELIVERY.

Authors:  John N Barry; Alexey A Vertegel
Journal:  Nano Life       Date:  2013-12-27

8.  Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation.

Authors:  Sergei Zaitsev; Dirk Spitzer; Juan-Carlos Murciano; Bi-Sen Ding; Samira Tliba; M Anna Kowalska; Oscar A Marcos-Contreras; Alice Kuo; Victoria Stepanova; John P Atkinson; Mortimer Poncz; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2010-04-21       Impact factor: 22.113

9.  Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis.

Authors:  Sergei Zaitsev; Sergei Zaitzev; Dirk Spitzer; Juan-Carlos Murciano; Bi-Sen Ding; Samira Tliba; M Anna Kowalska; Khalil Bdeir; Alice Kuo; Victoria Stepanova; John P Atkinson; Mortimer Poncz; Douglas B Cines; Vladimir R Muzykantov
Journal:  J Pharmacol Exp Ther       Date:  2009-12-01       Impact factor: 4.030

10.  Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.

Authors:  Lavanya Bondada; Ramu Rondla; Ugo Pradere; Peng Liu; Chengwei Li; Drew Bobeck; Tamara McBrayer; Philip Tharnish; Jerome Courcambeck; Philippe Halfon; Tony Whitaker; Franck Amblard; Steven J Coats; Raymond F Schinazi
Journal:  Bioorg Med Chem Lett       Date:  2013-09-30       Impact factor: 2.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.